Suggested remit: To appraise the clinical and cost effectiveness of imlunestrant within its marketing authorisation for treating oestrogen receptor-positive, HER2-negative advanced breast cancer after endocrine treatment.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6373
Provisional Schedule
- Expected publication:
- 10 September 2026
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 September 2025 | Invitation to participate |
| 25 October 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2025. |
| 11 June 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-November 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2025. |
| 25 April 2024 - 24 May 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6373 |
| 25 April 2024 | In progress. Scoping commencing |
| 25 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 25 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual